

LUCENTIS (ranibizumab)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

(Archived 1/22/19)

LUCENTIS is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use as an inhibitor of vascular endothelial growth factor.

Pre-Authorization Criteria: diabetic macular edema; macular edema following retinal vein occlusion; neovascular (“wet”) age-related macular degeneration; proliferative and non-proliferative diabetic retinopathy in patients with diabetic macular edema

Dosing: varies, depending on condition treated; see product information

PRECAUTIONS: post-injection endophthalmitis/increased intraocular pressure; retinal detachment; arterial thromboembolism (rare)

DRUG INTERACTIONS: none reported

REFERENCES

Gaudreault J, Fei D, Rusit J, et al, “Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) After a Single Intravitreal Administration,” *Invest Ophthalmol Vis Sci*, 2005, 46(2):726-33. [

Heier JS, Antoszyk AN, Pavan PR, et al, “Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: A Phase I/II Multicenter, Controlled, Multidose Study,” *Ophthalmology*, 2006, 113(4):633-42.

Massin P, Bandello F, Garweg JG, et al, "Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-Month, Randomized, Controlled, Double-Masked, Multicenter Phase II Study," *Diabetes Care*, 2010, 33(11):2399-405.

Mitchell P, Bandello F, Schmidt-Erfurth U, et al, "The RESTORE STUDY: Ranibizumab Monotherapy or Combined With Laser versus Laser Monotherapy for Diabetic Macular Edema," *Ophthalmology*, 2011, 118(4):615-25.

Rosenfeld PJ, Brown DM, Heier JS, et al, "Ranibizumab for Neovascular Age-Related Macular Degeneration," *N Engl J Med*, 2006, 355(14):1419-31.

Rosenfeld PJ, Rich RM and Lalwani, "Ranibizumab: Phase III Clinical Trial Results," *Ophthalmol Clin North Am*, 2006, 19(3):361-72.

REVISION HISTORY:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/Updated: 6/4./5 by R. Sterling, MD

Date Approved by P&T Committee: 7/28/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check ESI